Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Aromatase inhibitors versus tamoxifen for premenopausal women with hormone positive early-stage breast cancer treated with ovarian suppression.

Posted by on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...

Read More

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Posted by on Jun 5, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...

Read More

Reviewing common effects of hormonal therapy in patients with breast cancer.

Reviewing common effects of hormonal therapy in patients with breast cancer.

Posted by on May 23, 2021 in Breast cancer | 0 comments

In a nutshell This article reviewed the common side effects of estrogen deprivation during hormonal therapy for women with breast cancer and provided an update on alternative therapies to manage these symptoms. Some background Breast cancer (BC) is one of the most common cancers affecting women worldwide. Some BC cells grow in response to female...

Read More

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Comparing the real-world effectiveness of palbociclib plus letrozole versus letrozole alone in patients with advanced hormone-positive breast cancer

Posted by on May 16, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the real-world safety and effectiveness of the palbociclib (Ibrance) plus letrozole (Femara) versus letrozole alone in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC). The data concluded that palbociclib in combination with...

Read More

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Alpelisib and fulvestrant treatment for PIK3CA mutated, hormone receptor-positive, HER2-negative advanced breast cancer

Posted by on Jan 17, 2021 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the combination of alpelisib (Piqray) and fulvestrant (Faslodex) in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor 2 (HER2) negative, advanced breast cancer (BC).   This study concluded that this combination provided positive outcomes for...

Read More

Which is safer for the heart: tamoxifen or letrozole?

Which is safer for the heart: tamoxifen or letrozole?

Posted by on Nov 30, 2020 in Breast cancer | 0 comments

In a nutshell This study compared the safety of two hormonal medications used to treat breast cancer, tamoxifen (Nolvadex) and letrozole (Femara). This study found that tamoxifen was associated with an increased risk of blood clots, while letrozole was associated with an increased risk of angina and heart attacks. Some background Hormone-positive...

Read More

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Treating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor

Posted by on Oct 23, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...

Read More

Searching for patients with advanced breast cancer to trial an experimental drug combination

Searching for patients with advanced breast cancer to trial an experimental drug combination

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...

Read More